Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
NCT ID: NCT07228429
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
56 participants
OBSERVATIONAL
2025-11-30
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optical Elastography of Systemic Sclerosis Skin
NCT02835196
Intralesional Injection of STS in Treatment of Calcinosis
NCT06672822
Calcinosis in a Single-Center Scleroderma Population
NCT02062125
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic sclerosis participants with calcinosis
SSc participants with calcinosis treated with sodium thiosulfate STS per SOC over 6 months.
Sodium Thiosulfate (STS)
Calcinosis cutis treatment , Twice daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Thiosulfate (STS)
Calcinosis cutis treatment , Twice daily for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be ≥ 18 years old and meet the 2013 American College of Rheumatology criteria for the diagnosis of systemic sclerosis (diffuse or limited)
* Receiving clinical care at Yale clinics
Exclusion Criteria
* Currently pregnant or nursing
* Patients with a calcinosis ROI \>6cm
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monique Hinchcliff, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale Scleroderma Program
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000040280
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.